Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 3:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 420 matching trials from the live ClinicalTrials.gov search.
Conditions
ADHD, Comorbid Alcohol Abuse
Interventions
Atomoxetine, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
14
States / cities
El Centro, California • Poway, California • San Diego, California + 11 more
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
PF-03654746, Placebo capsules
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
7
States / cities
Lafayette, California • Los Alamitos, California • Newport Beach, California + 4 more
Conditions
ADHD, Parenting
Interventions
MomMA Intervention
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
ADHD
Interventions
Behavioral Parenting Intervention
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
5 Years to 12 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Hershey, Pennsylvania
Conditions
ADHD
Interventions
OROS methylphenidate, No intervention
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
12 Years to 18 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Cambridge, Massachusetts
Conditions
ADHD
Interventions
PRC-063 oral capsules, Placebo oral capsules
Drug
Lead sponsor
Purdue Pharma, Canada
Industry
Eligibility
18 Years to 60 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
8
States / cities
Bradenton, Florida • Lakeland, Florida • Maitland, Florida + 5 more
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Modafinil
Drug
Lead sponsor
Cephalon
Industry
Eligibility
6 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
23
States / cities
Little Rock, Arkansas • Irvine, California • San Francisco, California + 20 more
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
Choice, Recommendation
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Years to 11 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Attention Deficit Hyperactivity Disorder, Attention Deficit and Disruptive Behavior Disorders
Interventions
Immediate Treatment Group, Delayed Treatment Group
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
2 Years to 5 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Houston, Texas
Conditions
Alcoholism, Attention Deficit Disorder
Interventions
Methylphenidate
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Micronutrients for Attention-Deficit Hyperactivity Disorder in Youth (MADDY) Study

NCT03252522
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Broad Spectrum Micronutrients; a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants, Placebo
Combination Product · Dietary Supplement
Lead sponsor
Oregon Health and Science University
Other
Eligibility
6 Years to 12 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
2
States / cities
Columbus, Ohio • Portland, Oregon
Conditions
Attention Deficit and Disruptive Behavior Disorders
Interventions
Doctor-office collaborative care (DOCC) management, Treatment as usual (TAU)
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
5 Years to 12 Years
Enrollment
858 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
ADHD With Sleep Onset Insomnia
Interventions
Ramelteon, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
ADHD, Autism Spectrum Disorder
Interventions
Randomization to either Amphetamine (AMP) class of stimulant medication or Methylphenidate (MPH) class of stimulant medication, Randomization to either Alpha 2 agonist class of medication or alternate class of stimulant.
Drug
Lead sponsor
Daniel Coury
Other
Eligibility
4 Years to 17 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
11
States / cities
Irvine, California • Los Angeles, California • Portland, Maine + 8 more
Conditions
ADHD
Interventions
ADHD Therapy
Device
Lead sponsor
Lumos Labs, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
Jacksonville, Florida • Lakeland, Florida • Rochester Hills, Michigan + 2 more
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Guanfacine, Methylphenidate (MPH)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
7 Years to 14 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Conditions
ADHD
Interventions
Cognitive remediation and Parent Training
Behavioral
Lead sponsor
Queens College, The City University of New York
Other
Eligibility
7 Years to 11 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Flushing, New York
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children

NCT00178503
Conditions
Autism, Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate-extended release, Methylphenidate-immediate release, Placebo
Drug · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
7 Years to 12 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
1
States / cities
Houston, Texas
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
L-methylfolate, OROS-Methylphenidate, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Not applicable Interventional Accepts healthy volunteers

Student Outcomes of Integrative Mental Health Services

NCT02877875
Conditions
Anxiety, Depression, Trauma, Behavior Problems
Interventions
Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems, Monitoring and Feedback System, Treatment as usual
Behavioral · Other
Lead sponsor
Harvard University
Other
Eligibility
7 Years to 14 Years
Enrollment
143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Cambridge, Massachusetts
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
SPN-812
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Conditions
Attention-deficit/Hyperactivity Disorder, Autism Spectrum Disorder
Interventions
Methylphenidate extended-release liquid formulation
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 40 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Completed No phase listed Observational Accepts healthy volunteers

Stimulant Medication Effects on Auditory Sensitivity in Teens With ADHD

NCT04577417
Conditions
Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder, Attention Deficit Disorder With Hyperactivity
Interventions
ADHD stimulants, for example, amphetamine, dexmethylphenidate, dextroamphetamine, methylphenidate
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
13 Years to 19 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Wilmington, Delaware
Completed Phase 1Phase 2 Interventional Results available

CTx-1301 Comparative Bioavailability Study

NCT04138498
Conditions
ADHD
Interventions
Dexmethylphenidate 5 Mg Oral Capsule, Extended Release, Dexmethylphenidate 6.25 mg Tablet, Dexmethylphenidate 40 Mg Oral Capsule, Extended Release, Dexmethylphenidate 50 mg Tablet
Drug
Lead sponsor
Cingulate Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Overland Park, Kansas